Business, energy, technology, markets and global industry news from Business News Today

Serum Institute of India

PharmaDeviceNews Serum Institute of India
Representative image of clinical research vials and bladder cancer diagnostics, reflecting ImmunityBio’s Tokyo-172 BCG agreement with Japan BCG Laboratory and its potential role in easing the long-running U.S. BCG supply shortage for non-muscle invasive bladder cancer treatment.
Pharma & Biotech

Why ImmunityBio’s Japan BCG Laboratory agreement matters beyond bladder cancer supply

A bladder cancer supply crisis meets fresh Phase III data. ImmunityBio’s Tokyo BCG deal could test how flexible U.S. regulators are willing to be.

Read More
Pharma & Biotech

Serum Institute exits IXCHIQ rollout as Valneva resets LMIC strategy

Valneva ends its chikungunya vaccine deal with Serum Institute of India. Find out what this means for Asian access, LMIC rollout, and CEPI commitments.

Read More